Inozyme is a biopharmaceutical company specializing in the developing of novel therapeutics to treat rare metabolic diseases. The Company's area of expertise is disorders of paradoxical mineralization and its lead drug is an enzyme replacement therapy in pre-clinical development.
|HQ||Boston, MA, US||Map|
|Employees (est.) (Sept 2021)||53|
Inozyme total Funding
Inozyme latest funding size
Time since last funding
|2 years ago|
|New Enterprise Associates, Longitude Capital, Sofinnova Ventures, Novo Ventures, RA Capital Management, Rock Springs Capital, Sanofi-Genzyme BioVentures, Pivotal bioVenture Partners, Novo Holdings, Cowen Healthcare Investments|
When was Inozyme founded?
Inozyme was founded in 2016.
Who are Inozyme key executives?
Inozyme's key executives are Axel Bolte, Doug Treco and Henric Bjarke.
How many employees does Inozyme have?
Inozyme has 53 employees.
Who are Inozyme competitors?
Competitors of Inozyme include Integra, Aquinnah Pharmaceuticals and Batavia Biosciences.
Where is Inozyme headquarters?
Inozyme headquarters is located at 321 Summer St #400, Boston.
Where are Inozyme offices?
Inozyme has an office in Boston.
How many offices does Inozyme have?
Inozyme has 3 offices.
Receive alerts for 300+ data fields across thousands of companies